297 related articles for article (PubMed ID: 25918346)
1. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Saussele S; Krauss MP; Hehlmann R; Lauseker M; Proetel U; Kalmanti L; Hanfstein B; Fabarius A; Kraemer D; Berdel WE; Bentz M; Staib P; de Wit M; Wernli M; Zettl F; Hebart HF; Hahn M; Heymanns J; Schmidt-Wolf I; Schmitz N; Eckart MJ; Gassmann W; Bartholomäus A; Pezzutto A; Leibundgut EO; Heim D; Krause SW; Burchert A; Hofmann WK; Hasford J; Hochhaus A; Pfirrmann M; Müller MC;
Blood; 2015 Jul; 126(1):42-9. PubMed ID: 25918346
[TBL] [Abstract][Full Text] [Related]
2. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
Hehlmann R; Müller MC; Lauseker M; Hanfstein B; Fabarius A; Schreiber A; Proetel U; Pletsch N; Pfirrmann M; Haferlach C; Schnittger S; Einsele H; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Ehninger G; Heim D; Heimpel H; Nerl C; Krause SW; Hossfeld DK; Kolb HJ; Hasford J; Saußele S; Hochhaus A
J Clin Oncol; 2014 Feb; 32(5):415-23. PubMed ID: 24297946
[TBL] [Abstract][Full Text] [Related]
3. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
[TBL] [Abstract][Full Text] [Related]
4. Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.
Ono T; Takahashi N; Kizaki M; Kawaguchi T; Suzuki R; Yamamoto K; Ohnishi K; Naoe T; Matsumura I
Cancer Sci; 2020 Oct; 111(10):3714-3725. PubMed ID: 33404088
[TBL] [Abstract][Full Text] [Related]
5. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Berger U; Hehlmann R
Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
[No Abstract] [Full Text] [Related]
6. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
[TBL] [Abstract][Full Text] [Related]
7. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
Guilhot F; Druker B; Larson RA; Gathmann I; So C; Waltzman R; O'Brien SG
Haematologica; 2009 Dec; 94(12):1669-75. PubMed ID: 19648168
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Saussele S; Lauseker M; Gratwohl A; Beelen DW; Bunjes D; Schwerdtfeger R; Kolb HJ; Ho AD; Falge C; Holler E; Schlimok G; Zander AR; Arnold R; Kanz L; Dengler R; Haferlach C; Schlegelberger B; Pfirrmann M; Müller MC; Schnittger S; Leitner A; Pletsch N; Hochhaus A; Hasford J; Hehlmann R;
Blood; 2010 Mar; 115(10):1880-5. PubMed ID: 19965667
[TBL] [Abstract][Full Text] [Related]
9. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.
Eşkazan AE; Özmen D; Öztaş M; Bektaş F; Bayraktar EA; Sadri S; Keskin D; Özgür Yurttaş N; Elverdi T; Salihoğlu A; Ar MC; Öngören Ş; Başlar Z; Aydın Y; Soysal T
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):549-557. PubMed ID: 34052176
[TBL] [Abstract][Full Text] [Related]
12. [Imatinib combination therapies--the new CML Study 4].
Helmann R; Berger U; Engelich G
Dtsch Med Wochenschr; 2002 Oct; 127(42):224-6. PubMed ID: 12430568
[No Abstract] [Full Text] [Related]
13. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
14. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
15. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Proetel U; Pletsch N; Lauseker M; Müller MC; Hanfstein B; Krause SW; Kalmanti L; Schreiber A; Heim D; Baerlocher GM; Hofmann WK; Lange E; Einsele H; Wernli M; Kremers S; Schlag R; Müller L; Hänel M; Link H; Hertenstein B; Pfirrman M; Hochhaus A; Hasford J; Hehlmann R; Saußele S; ;
Ann Hematol; 2014 Jul; 93(7):1167-76. PubMed ID: 24658964
[TBL] [Abstract][Full Text] [Related]
16. [Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
Hochhaus A; Berger U; Reiter A; Engelich G; Lahaye T; Kreil S; Merx K; Müller MC; Hehlmann R
Internist (Berl); 2002 Oct; 43(10):1228, 1231-8, 1241-4. PubMed ID: 12524904
[No Abstract] [Full Text] [Related]
17. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
18. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
19. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
